1Feinberg School of Medicine, Northwestern University; and.
Departments of2Neurological Surgery and.
J Neurosurg. 2020 May 22;134(5):1610-1617. doi: 10.3171/2020.3.JNS193231. Print 2021 May 1.
Intraoperative stimulation has emerged as a crucial adjunct in neurosurgical oncology, aiding maximal tumor resection while preserving sensorimotor and language function. Despite increasing use in clinical practice of this stimulation, there are limited data on both intraoperative seizure (IS) frequency and the presence of afterdischarges (ADs) in patients undergoing such procedures. The objective of this study was to determine risk factors for IS or ADs, and to determine the clinical consequences of these intraoperative events.
A retrospective chart review was performed for patients undergoing awake craniotomy (both first time and repeat) at a single institution from 2013 to 2018. Hypothesized risk factors for ADs/ISs in patients were evaluated for their effect on ADs and ISs, including tumor location, tumor grade (I-IV), genetic markers (isocitrate dehydrogenase 1/2, O 6-methylguanine-DNA methyltransferase [MGMT] promoter methylation, chromosome 1p/19q codeletion), tumor volume, preoperative seizure status (yes/no), and dosage of preoperative antiepileptic drugs for each patient. Clinical outcomes assessed in patients with IS or ADs were duration of surgery, length of stay, presence of perioperative deficits, and postoperative seizures. Chi-square analysis was performed for binary categorical variables, and a Student t-test was used to assess continuous variables.
A total of 229 consecutive patients were included in the analysis. Thirty-five patients (15%) experienced ISs. Thirteen (37%) of these 35 patients had experienced seizures that were appreciated clinically and noted on electrocorticography simultaneously, while 8 patients (23%) experienced ISs that were electrographic alone (no obvious clinical change). MGMT promoter methylation was associated with an increased prevalence of ISs (OR 3.3, 95% CI 1.2-7.8, p = 0.02). Forty patients (18%) experienced ADs. Twenty-three percent of patients (9/40) with ISs had ADs prior to their seizure, although ISs and ADs were not statistically associated (p = 0.16). The presence of ADs appeared to be correlated with a shorter length of stay (5.1 ± 2.6 vs 6.1 ± 3.7 days, p = 0.037). Of the clinical features assessed, none were found to be predictive of ADs. Neither IS nor AD, or the presence of either IS or AD (65/229 patients), was a predictor for increased length of stay, presence of perioperative deficits, or postoperative seizures.
ISs and ADs, while commonly observed during intraoperative stimulation for brain mapping, do not negatively affect patient outcomes.
术中刺激已成为神经外科肿瘤学中的重要辅助手段,有助于在保留感觉运动和语言功能的同时实现最大程度的肿瘤切除。尽管这种刺激在临床实践中的应用越来越多,但关于接受此类手术的患者术中发作(IS)的频率和迟发性放电(ADs)的存在的数据有限。本研究的目的是确定 IS 或 ADs 的危险因素,并确定这些术中事件的临床后果。
对 2013 年至 2018 年在单一机构接受清醒开颅术(初次手术和重复手术)的患者进行回顾性图表审查。评估了患者发生 ADs/IS 的假设危险因素对 ADs 和 IS 的影响,包括肿瘤位置、肿瘤分级(I-IV)、遗传标志物(异柠檬酸脱氢酶 1/2、O6-甲基鸟嘌呤-DNA 甲基转移酶 [MGMT] 启动子甲基化、染色体 1p/19q 缺失)、肿瘤体积、术前癫痫发作状态(是/否)和每位患者的术前抗癫痫药物剂量。评估了发生 IS 或 AD 的患者的临床结局,包括手术持续时间、住院时间、围手术期缺陷的存在和术后癫痫发作。对于二项分类变量进行卡方分析,对于连续变量进行学生 t 检验。
共纳入 229 例连续患者进行分析。35 例(15%)患者出现 ISs。其中 13 例(37%)患者的 ISs 同时伴有临床注意到的癫痫发作和皮质电图记录,而 8 例(23%)患者的 ISs 仅为皮质电图表现(无明显临床改变)。MGMT 启动子甲基化与 ISs 的发生率增加相关(比值比 3.3,95%置信区间 1.2-7.8,p = 0.02)。40 例(18%)患者出现 ADs。23%(9/40)出现 IS 的患者在发作前出现 ADs,尽管 IS 和 ADs 之间无统计学关联(p = 0.16)。ADs 的存在似乎与较短的住院时间相关(5.1±2.6 与 6.1±3.7 天,p = 0.037)。在评估的临床特征中,没有发现任何特征可预测 ADs。IS 或 AD 均未导致住院时间延长、围手术期缺陷或术后癫痫发作,且同时存在 IS 或 AD(65/229 例患者)也未增加上述风险。
虽然术中刺激进行脑映射时经常观察到 IS 和 ADs,但它们不会对患者的结局产生负面影响。